Clinicopathologic features and KRAS mutation incidence of gastric carcinomas
Journal of Contemporary Medicine
Objectives: This study aimed to determine the frequency of KRAS mutations in patients with gastric adenocarcinoma (GAC) in Hatay Province and the relationship of these mutations with some pathological and clinical parameters, and to guide the diagnosis and treatment planning of patients. Material and Method: Formalin-fixed, paraffin-embedded and histologically confirmed samples were used in the assessment of KRAS mutation. The sections were taken from the archive tissue samples of each case.
... l-Time Polymerase Chain Reaction (RT-PCR) system was used to identify the mutations of codons 12 and 13 (exon 2) of the RAS gene. The mutations GLY12ALA (G12A), GLY12ASP (G12D), GLY12ARG (G12R), GLY12CYS (G12C), GLY12SER (G12S), GLY12VAL (G12V) and GLY13ASP (G13D) were investigated. Results: The KRAS mutation rate was 2% and only G12D substitution was detected. In this case, the tumor was located in the small curvature. No statistical comparison could be carried out between KRAS mutation and clinicopathological factors due to the small number of the mutated cases. Tumor differentiation was found significantly different from WHO-2010 typing and primary tumor staging. Conclusions: We have found the incidence of KRAS mutation to be 2%. Even though, KRAS mutation in GAC alone is not a prognostic or predictive marker, subtype-specific analysis can provide data that may affect the diagnosis, management and treatment of the disease.